NRTS AS TREATMENT IN PARKINSONS DISEASE

Information

  • Research Project
  • 2272264
  • ApplicationId
    2272264
  • Core Project Number
    R43NS033438
  • Full Project Number
    1R43NS033438-01
  • Serial Number
    33438
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1994 - 30 years ago
  • Project End Date
    2/28/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1994 - 30 years ago
  • Budget End Date
    2/28/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/30/1994 - 30 years ago

NRTS AS TREATMENT IN PARKINSONS DISEASE

DESCRIPTION (Adapted from applicant's abstract): Oxygen free radicals and oxidative damage have been shown to be involved in neurodegenerative diseases including Parkinson's Disease. The PI has discovered that certain nitrone-based free radical traps (NRTs), which react with and trap free radicals, protect experimental animals from an experimental model of Parkinson's Disease, the MPTP (l-methyl-4-phenyl-1,2,5,6- tetrahydropyridine)-induced loss of caudate dopamine in C57BL/6 mice. They have also discovered that MPTP induces increased hydroxyl free radical formation in treated mice. The overall goal of this Phase I proposal is to determine if NRTs protect in experimental models of Parkinson's Disease. The specific aims are: (1) to determine if, during MPTP-induced Parkinson's Disease, the tissue is injured by oxidative damage; (2) to determine the effectiveness of a series of NRTs in preventing brain damage as assessed by dopamine caudate loss and determine if NRTs protect by reacting with either the primary reactive oxygen species (ROS) or their secondary reaction products and thus prevent the oxidative cascade of events which leads to tissue injury; and (3) to synthesize and test NRTs that have potential effectiveness in treating Parkinson's Disease patients.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    CENTAUR PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SUNNYVALE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940854708
  • Organization District
    UNITED STATES